Real-World Treatment Patterns in Patients with Atopic Dermatitis Initiating Ruxolitinib Cream: A 12-Month Follow-Up...

Area of Science:

• Dermatology and Immunology
• Pharmacotherapy
• Real-World Evidence

Background:

• Atopic dermatitis (AD) is a chronic inflammatory skin condition with significant impact on quality of life.
• Current treatments for AD include topical and systemic therapies, with varying efficacy and side effect profiles.
• Ruxolitinib cream offers a novel therapeutic option for AD management.

Purpose of the Study:

• To characterize treatment patterns in US commercially insured and Medicare Advantage patients with AD before and after initiating ruxolitinib cream.
• To evaluate changes in the use of other AD therapies, including corticosteroids and biologics, during a 12-month follow-up period.
• To assess healthcare resource utilization among AD patients treated with ruxolitinib cream.

Main Methods:

• Retrospective, observational cohort study utilizing administrative claims and social drivers of health data.
• Analysis of 556 patients diagnosed with AD and treated with ruxolitinib cream.
• Comparison of treatment patterns and healthcare encounters in the 6 months preceding and 12 months following ruxolitinib cream initiation.

Main Results:

• Ruxolitinib cream initiation was associated with a decrease in topical corticosteroid use (31.3% to 26.6%) and a reduction in the mean cumulative prednisone-equivalent dose by 28.9% among systemic corticosteroid users.
• Among biologic-naïve patients, 90.0% remained biologic-free during follow-up.
• Healthcare encounters for AD decreased from 85.3% at baseline to 70.0% during the follow-up period.

Conclusions:

• Reduced use of corticosteroids and sustained biologic-free status suggest the durable effectiveness of ruxolitinib cream in AD management.
• Ruxolitinib cream represents a valuable therapeutic option for adults and adolescents with atopic dermatitis.
• The findings support the role of ruxolitinib cream in simplifying treatment regimens and potentially reducing healthcare resource utilization in AD patients.